Join us at SLAS Barcelona

Festo LifeTech is exhibiting at the SLAS in Barcelona.

Uncertainty about the government’s life science work

The government’s national coordinator for life science, Jenni Nordborg, left her position almost four months ago. No one has yet succeeded her, and now question...

Final assembly inspection of medical plastics

Technical paper by ZEISS Medical Industry Solutions.

Accelerate your Research with AI-Powered Image Analysis

Comprehensive eBook from ZEISS.

Anna Törner: The minute between life and death

“I have never told anyone about this day that happened more than 20 years ago. But I sometimes reflect on what happened, on what might have happened. When I try...

“Life science is important on a personal level”

From the High Coast to the Government Offices. Jeanette Edblad is a native of Ångermanland, and since September last year, she has been Head and Coordinator of ...

Labbmöte igång i Life City - Ultrasnabb diagnostik och nya virus på agendan

Life Science Swedens konferens om laboratoriemedicin och diagnostik har nu inletts i Life City i Stockholm.

Ny kurs ska väcka passion för statistik – ”Många får panik”

Kan man förstå och tolka kliniska studier – utan att vara bra på matte? Ja, menar Anna Törner som tillsammans med Ingrid Lönnstedt skapat en onlinekurs för att ...

The TFS family is growing

TFS HealthScience is a European based CRO company with broad expertise and experiences in the biotech and pharmaceutical sector. The company is growing and the ...

A surprising discovery about the immune system in cases of cancer

Professor Göran Jönsson is trying to understand why some patients benefit from immunotherapies while others don’t. A couple of years ago, he made a surprising d...

A new special edition and a new event in Copenhagen – This is happening at Life Science Sweden 2024

The new year brings new features for the readers of Life Science Sweden.

Decades of research destroyed at KI – a hacker attack cannot be ruled out!

Years of research, together with half a billion Swedish krona, went up in smoke when the freezers at Karolinska Institutet overheated. The breakdown has now bee...

Bioscience – Groundbreaking Research & Diagnostics: Gothenburg 2026

Ranking: Top 10 highest-paid CEOs in pharma

It's nice to hear that things go well for others, right? Some of those who have done really well – at least financially – are listed here in the ranking of the ...

A mass flow controller that is silent, fast and cost-effective

Portable ventilator breathing devices, bioreactors or the dosing of inert gases all rely on the highest control dynamics. That is exactly what the proportional ...

"Are we doing business the wrong way around in the Life Science Sector?"

For the past 50 years we have created solutions for problems that we thought would solve the problems. Pharmaceuticals have created big block buster drugs which...

The first Lyme disease vaccine faces a delay

Pfizer and Valneva’s Lyme disease vaccine, which could be the first of its kind, is facing delays of about a year. The reason is problems at trial sites in the ...

New drug alert in the US: Rise in overdoses linked to the use of drugs for animals

A combination of the synthetic drugs fentanyl and xylazine, an animal tranquilizer, has been labelled a “growing threat” by the White House due to its role in t...

Conjugate Planes in Microscopy

Knowledge Article from ZEISS.

The first pharmaceutical for eosinophilic esophagitis approved in the U.S.

The U.S. Drug Administration has approved the drug Dupixent (dupilumab) to treat inflammation of the oesophagus of the type eosinophil esophagitis.

Automated nitrogen analysis reduces costs per sample

N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo

Learn from Speakers from Leading MedTech Companies

Watch the recordings from ZEISS Quality Innovation Days whenever it suits you.

From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”

A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...

EMA review confirms a risk of new cancer after CAR-T

CAR-T cancer therapies can, in rare cases, induce secondary cancers. The European Medicines Agency (EMA) now recognises this and requires a warning label to be ...